- My News
- All News
- Most Popular
A study published in Science and Technology of Advanced Materials suggests a micro-sized device has been developed for quick, accurate identification of a mutation strongly associated with gliomas, Science Daily reported Wednesday.
The immuno-wall microdevice features a chip with an attached highly specific antibody, HMab-2, that binds to the protein produced by the gene in which the mutation has occurred.
"The immuno-wall determines whether a sample is positive for a specific mutation in the isocitrate dehydrogenase 1 gene, which is present in around 70 percent to 80 percent of grade II and III gliomas," said coauthor Toshihiro Kasama.
"Our results for a range of cancerous cell lines and actual tumour samples both positive and negative for this mutation were very promising," Kasama added.
Lead author Akane Yamamichi noted that "our data indicate that a sample with just 500 cells or 500 ng of protein is sufficient to give a positive result."
Yamamichi said "the key to success in the immuno-wall assay is that we, luckily, have HMab-2, the highly specific antibody to the mutant IDH1. This means the immuno-wall can identify the margins of tumours where only low numbers of cancerous cells are present."
Did you like this article?